4051 Basel, ch
+41 (61) 20640-25
Speedel retains all development & commercialisation Rights to SPP200
Promising safety and efficacy results from Phase II trial in patients undergoing chronic haemodialysis for end-stage renal disease
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to email@example.com.